Grifols spending $460 million on plasma facilities

20 July 2020

Spanish plasma-derived medicines company Grifols (GRF: MC) today announced it has executed purchase arrangements with the South Korean-based GC Pharma (KRX: 0062800; formerly known as Green Cross Corporation) whereby Grifols will acquire the Montreal, Canada-based plasma fractionation facility and two purification facilities, along with 11 USA-based plasma collection centers.

Grifols will pay a total amount of $460 million for the acquisition, with the news pushing the shares of GC Pharma up 16.8% to 218,500 Korean won by close of trading today, while the Spanish firm’s stock gained 2.56% to 27.64 by early afternoon. The completion of the transaction is subject to regulatory approvals and is expected to close prior to the end of 2020.

Building on a legacy of partnership in Canada's blood system

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK